Control of nephrotoxicity by hydration-diuresis, and of emesis by alizapride, during cisplatin administration in patients with bladder cancer.
Neri
B
B
Bartalucci
S
S
Rizzo
P
P
Nicita
G
G
Ponchietti
R
R
D000368:Aged; D000932:Antiemetics / Q000627:therapeutic use*; D002945:Cisplatin / Q000009:adverse effects* / Q000627:therapeutic use; D004231:Diuresis; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D011759:Pyrrolidines / Q000627:therapeutic use*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*; D001613:beta 2-Microglobulin / Q000378:metabolism
D000932:Antiemetics; D011759:Pyrrolidines; D001613:beta 2-Microglobulin; C033968:alizapride; D002945:Cisplatin